垂体功能减退症患者非酒精性脂肪性肝病发生情况及其相关激素水平变化*

doi:10.3969/j.issn.1672-5069.2023.04.013

摘要/Abstract

摘要： 目的探讨垂体功能减退症(HP)患者合并非酒精性脂肪性肝病(NAFLD)情况及其血清游离甲状腺素(FT₄)水平和FT₃/FT₄比值变化,以探讨甲状腺功能与NAFLD发生之间的关系。方法 2018年1月～2022年6月我院诊治的HP患者32例和NAFLD患者30例,使用超声行腹部检查。采用ELISA法检测血清游离三碘甲状腺原氨酸(FT₃)、FT4、促甲状腺激素(TSH)、促肾上腺皮质激素(ACTH)、皮质醇(Cor)、生长激素(GH)和胰岛素样生长因子-1(IGF-1)。结果在本组32例HP患者中,经超声检查诊断合并NAFLD者17例;HP合并NAFLD组体质指数、血清ALT、AST、GGT、LDH和TG水平分别为(27.4±3.6)kg/m²、76.7(36.3,328.6) U/L、65.2(38.5,335.2)U/L、68.5(32.2,82.5)U/L、(313.5 ± 55.3)U/L和(2.1±0.7)mmol/L,均显著高于HP组【分别为(23.4±1.5)kg/m²、16.2(10.4,23.6)U/L、18.1(14.5,25.9)U/L、36.0(12.5,43.5)U/L、(198.1 ± 47.3)U/L和(1.3±1.2)mmol/L,P<0.05】,而血清HDL水平为(0.8±0.6)mmol/L,显著低于HP组【(1.2±0.5)mmol/L,P<0.05】;HP合并NAFLD组血清FT₄和GH水平分别为9.4(7.3,12.7)pmol/L和0.05(0.04,0.10) ng/mL,显著低于HP组【分别为12.3(8.8,15.3)pmol/L和0.1(0.05,0.2)ng/mL,P<0.05】,而血清FT₃/FT₄比值为0.4(0.3,0.4),显著大于HP组【0.2(0.2,0.4),P<0.05】,血清TSH、FT₄和GH水平分别为1.3(0.4,3.3)μIU/mL、9.4(7.3,12.7)pmol/L和0.05(0.04,0.10) ng/mL,显著低于NAFLD组【分别为2.8(1.4,4.5)μIU/mL、16.5(11.6,24.9)pmol/L和0.1(0.05,0.3)ng/mL,P<0.05】,而血清FT₃/FT₄比值显著大于NAFLD组【0.2(0.1,0.3),P<0.05】。结论垂体功能减退可能通过改变全身激素水平而影响脂质代谢,导致NAFLD的发生。

关键词: 非酒精性脂肪性肝病, 垂体功能减退症, 甲状腺功能减退

Abstract: Objective This study aimed to the prevalence of non-alcoholic fatty liver diseases (NAFLD) in patients with hypopituitarism (HP), and to clarify the relationship between thyroid functions and the occurrence of NAFLD. Methods 32 patients with HP and 30 patients with NAFLD were enrolled in our hospital between January 2018 and June 2022, and all underwent ultrasonography to determine the diagnosis of NAFLD. Serum free triiodothyronine (FT₃), free thyroxine (FT4), thyroid-stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH), cortisol (Cor), growth hormone (GH) and insulin-like growth factor -1 (IGF-1) were detected by ELISA. Results Out of 32 patients with HP in our series, the ultrasonography revealed NAFLD in 17 cases; the body mass index, serum ALT, AST, GGT, lactate dehydrogenase and triglyceride levels in patients with HP and NAFLD were(27.4±3.6)kg/m², 76.7(36.3, 328.6) U/L, 65.2(38.5, 335.2)U/L, 68.5(32.2, 82.5)U/L, (313.5 ± 55.3)U/L and (2.1±0.7)mmol/L, all significantly higher than [(23.4±1.5)kg/m², 16.2(10.4, 23.6)U/L, 18.1(14.5, 25.9)U/L, 36.0(12.5, 43.5)U/L, (198.1 ± 47.3)U/L and (1.3±1.2)mmol/L, respectively, P<0.05], while serum high-density lipoprotein level was (0.8±0.6)mmol/L, much lower than [(1.2±0.5)mmol/L, P<0.05] in patients with HP; serum FT₄ and GH levels in patients with HP and NAFLD were 9.4(7.3, 12.7)pmol/L and 0.05(0.04, 0.10) ng/mL, much lower than [12.3(8.8, 15.3)pmol/L and 0.1(0.05, 0.2)ng/mL, P<0.05] in patients with HP, while the FT₃/FT₄ ratio was 0.4(0.3, 0.4), much greater than [0.2(0.2, 0.4), P<0.05] in patients with HP; serum TSH, FT₄ and GH levels were 1.3(0.4, 3.3)μIU/mL, 9.4(7.3, 12.7)pmol/L and 0.05(0.04, 0.10) ng/mL, significantly lower than [2.8(1.4, 4.5)μIU/mL, 16.5(11.6, 24.9)pmol/L and 0.1(0.05, 0.3)ng/mL, P<0.05], while the FT₃/FT₄ ratio was significantly greater than [0.2(0.1, 0.3), P<0.05] in patients with NAFLD. Conclusion The hypothyroidism could disturb systemic lipid metabolism, which might lead to the occurrence of NAFLD.

Key words: Nonalcoholic fatty liver diseases, Hypopituitarism, Hypothyroidism

方山山, 杜明桥, 王玥. 垂体功能减退症患者非酒精性脂肪性肝病发生情况及其相关激素水平变化^*[J]. 实用肝脏病杂志, 2023, 26(4): 504-507.

Fang Shanshan, Du Mingqiao, Wang Yue. Will the hypopituitarism lead to the occurrence of nonalcoholic fatty liver diseases? An preliminary study[J]. Journal of Practical Hepatology, 2023, 26(4): 504-507.

参考文献

[1] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019, 69(6): 2672-2682.
[2] Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol, 2019, 17(4): 748-755 e743.
[3] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the americanassociation for the study of liver diseases. Hepatology, 2018, 67(1): 328-357.
[4] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology, 2020, 158(7): 1851-1864.
[5] Miljic D, Popovic V. Metabolic syndrome in hypopituitarism. Front Horm Res, 2018, 49: 1-19.
[6] Rufinatscha K, Ress C, Folie S, et al. Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatol Int, 2018, 12(5): 474-481.
[7] Ozturk A, Grajo JR, Gee MS, et al. Quantitative hepatic fat quantification in non-alcoholic fatty liver disease using ultrasound-based techniques: a review of literature and their diagnostic performance. Ultrasound Med Biol, 2018, 44(12): 2461-2475.
[8] Yuan XX, Zhu HJ, Pan H, et al.Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol, 2019, 25(14): 1741-1752.
[9] Yang Y, Qi ZR, Zhang TT, et al. Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases. Neuro Endocrinol Lett, 2018, 39(2): 99-104.
[10] Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol, 2020, 17(1): 40-52.
[11] Sun X, Chen L, Wu R, et al.Association of thyroid hormone with body fat content and lipid metabolism in euthyroid male patients with type 2 diabetes mellitus: a cross-sectional study. BMC Endocr Disord, 2021, 21(1): 241.
[12] Lisowska-Myjak B, Zborowska H, Bialek S, et al. Exploring associations of anthropometric parameters and serum triglycerides with serum thyroid hormones in young women. Sci Rep, 2022, 12(1): 17374.
[13] Huang B, Yang S, Ye S. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid type 2 diabetes patients.J Diabetes Res, 2020, 2020: 6538208.
[14] Guo Z, Li M, Han B, et al.Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis. Dig Liver Dis, 2018, 50(11): 1153-1162.
[15] Urrunaga-Pastor D, Guarnizo-Poma M, Moncada-Mapelli E, et al. High free triiodothyronine and free-triiodothyronine-to-free-thyroxine ratio levels are associated with metabolic syndrome in a euthyroid population. Diabetes Metab Syndr, 2018, 12(2): 155-161.
[16] Stepanek L, Horakova D, Stepanek L, et al. Free triiodothyronine/free thyroxine (FT3/FT4) ratio is strongly associated with insulin resistance in euthyroid and hypothyroid adults: a cross-sectional study. Endokrynol Pol, 2021, 72(1): 8-13.
[17] Xu R, Huang F, Zhang S, et al. Thyroid function, body mass index, and metabolic risk markers in euthyroid adults: a cohort study. BMC Endocr Disord, 2019, 19(1): 58.
[18] Cannarella R, Musmeci M, Garofalo V, et al. Resistance to thyroid hormones: a case-series study. Int J Mol Sci, 2022, 23(19).
[19] Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid, 2019, 29(9): 1173-1191.
[20] Bruinstroop E, Dalan R, Cao Y, et al. Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD. J Clin Endocrinol Metab, 2018, 103(7): 2698-2706.

垂体功能减退症患者非酒精性脂肪性肝病发生情况及其相关激素水平变化^*

Will the hypopituitarism lead to the occurrence of nonalcoholic fatty liver diseases? An preliminary study

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	顾棨, 芮法娟, 倪文婧, 陈倩倩, 吴超, 施军平, 李婕. 非酒精性脂肪性肝病的规范化管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 457-459.
[2]	何方平. 我国NAFLD慢病管理实践现状和建议[J]. 实用肝脏病杂志, 2023, 26(4): 460-462.
[3]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[4]	尹会芬, 于红艳, 刘志平. 非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 500-503.
[5]	邱丽瑛, 王迎春. 非酒精性脂肪性肝病与肠道微生态[J]. 实用肝脏病杂志, 2023, 26(3): 308-312.
[6]	湛栖睿, 段太美, 闫洁. 非酒精性脂肪性肝病患者血清淀粉样蛋白A、血浆血红素氧合酶1和骨形成蛋白9水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 348-351.
[7]	赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 356-359.
[8]	黄慧, 林敏, 曾桂香. 肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*[J]. 实用肝脏病杂志, 2023, 26(3): 364-367.
[9]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[10]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[11]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[12]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[13]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[14]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[15]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.